Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02257151 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

A Phase 1 study of Healthy Adult, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
118
Enrollment target
1
Study location

NCT02257151 is a Phase 1 study of Healthy Adult that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 118 participants, above the 59-participant average among 8 other Healthy Adult trials with a reported enrollment target (100% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02257151, a Phase 1 study of Healthy Adult, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
118 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and target engagement of BMS-986142 in healthy subjects.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG BMS-986142

Study Locations (1)

California

  • Wcct Global, Llc - Cypress

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2014-09
Est. Completion 2015-08
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT02257151

The ClinicalTrials.gov registry entry for NCT02257151 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 8 other Healthy Adult trials with a reported enrollment target (100% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Adult appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02257151 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02257151 about?

NCT02257151 is a clinical study titled "Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects". The purpose of this study is to evaluate the safety, pharmacokinetics, and target engagement of BMS-986142 in healthy subjects.

What is the current status of trial NCT02257151?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2014-09. Estimated completion is 2015-08.

What conditions does trial NCT02257151 study?

This clinical trial studies the following conditions: Healthy Adult.

What interventions are being tested in trial NCT02257151?

The interventions under investigation include: Placebo (DRUG), BMS-986142 (DRUG).

Who is sponsoring clinical trial NCT02257151?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02257151 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.